The Effects of Co-transplantation of Olfactory Ensheathing Cells and Schwann Cells on Local Inflammation Environment in the Contused Spinal Cord of Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response following spinal cord injury -LRB- SCI -RRB-	1
The Effects	1
Co-transplantation of Olfactory Ensheathing Cells and Schwann Cells on Local Inflammation Environment in the Contused Spinal Cord of Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response	16
Co-transplantation of Olfactory Ensheathing Cells	16
Co-transplantation	16
Olfactory Ensheathing Cells	38
Schwann Cells on Local Inflammation Environment in the Contused Spinal Cord of Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response	70
Schwann Cells	70
Local Inflammation Environment in the Contused Spinal Cord of Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response	87
Local Inflammation Environment	87
the Contused Spinal Cord of Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response	121
the Contused Spinal Cord	121
Rats Jieyuan Zhang1 & Huijun Chen1 & Zhaoxia Duan1 & Kuijun Chen1 & Zeng Liu1 & Lu Zhang1 & Dongdong Yao1 & Bingcang Li1 Abstract Inflammatory response	149
spinal cord injury -LRB- SCI -RRB-	313
spinal cord injury	313
SCI	333
regulation of the repair process	354
regulation	354
the repair process	368
Olfactory ensheathing cells -LRB- OECs -RRB- and Schwann cells -LRB- SCs -RRB-	388
Olfactory ensheathing cells -LRB- OECs -RRB-	388
Olfactory ensheathing cells	388
OECs	417
Schwann cells -LRB- SCs -RRB-	427
Schwann cells	427
SCs	442
important donor cells for repairing SCI in different animal models	451
important donor cells	451
SCI in different animal models	487
SCI	487
different animal models	494
synergistic or complementary effects of co-transplantation of both cells for this purpose	528
synergistic or complementary effects	528
co-transplantation of both cells for this purpose	568
co-transplantation	568
both cells for this purpose	590
both cells	590
this purpose	605
the present study	661
we	680
the effects of co-transplantation of OECs and SCs	696
the effects	696
co-transplantation of OECs and SCs	711
co-transplantation	711
OECs and SCs	733
expression of pro- or anti-inflammatory factor and polarization of macrophages in the injured spinal cord of rats	749
expression of pro- or anti-inflammatory factor	749
expression	749
pro- or anti-inflammatory factor	763
polarization of macrophages in the injured spinal cord of rats	800
polarization	800
macrophages in the injured spinal cord of rats	816
macrophages	816
the injured spinal cord of rats	831
the injured spinal cord	831
rats	858
Mixed cell suspensions containing OECs and SCs	864
Mixed cell suspensions	864
OECs and SCs	898
the injured site at 7 days	934
the injured site	934
7 days	954
contusion	967
the vertebral T10 level	980
the DMEM , SC , or OEC group	1019
the co-transplantation group	1047
a more extensive distribution of the grafted cells	1080
a more extensive distribution	1080
the grafted cells	1113
number of astrocytes , microglia/macrophage infiltration , and expression of chemokines -LRB- CCL2 and CCL3 -RRB-	1157
number	1157
astrocytes , microglia/macrophage infiltration , and expression of chemokines -LRB- CCL2 and CCL3 -RRB-	1167
astrocytes	1167
microglia/macrophage infiltration	1179
expression of chemokines -LRB- CCL2 and CCL3 -RRB-	1218
expression	1218
chemokines -LRB- CCL2 and CCL3 -RRB-	1232
chemokines	1232
CCL2 and CCL3	1244
CCL2	1244
CCL3	1253
the injured site	1262
The co-transplantation group	1280
arginase + / CD206 + macrophages -LRB- IL-4 -RRB-	1338
arginase + / CD206 + macrophages	1338
arginase +	1338
arginase	1338
+	1346
CD206 + macrophages	1348
CD206	1348
macrophages	1355
IL-4	1368
iNOS	1388
+	1392
CD16/32 + macrophages -LRB- IFN-γ -RRB- , which was followed by higher IL-10 and IL-13 and lower IL-6 and TNF-α in their expression levels , a smaller cystic cavity area ,	1395
CD16/32 + macrophages -LRB- IFN-γ -RRB- , which was followed by higher IL-10 and IL-13	1395
CD16/32 + macrophages	1395
IFN-γ	1417
higher IL-10 and IL-13	1447
higher IL-10	1447
IL-13	1464
lower IL-6 and TNF-α in their expression levels , a smaller cystic cavity area ,	1474
lower IL-6 and TNF-α	1474
their expression levels , a smaller cystic cavity area ,	1498
their expression levels	1498
a smaller cystic cavity area	1523
motor functions	1566
These results	1583
OEC and SC co-transplantation	1611
the shift of the macrophage phenotype	1655
the shift	1655
the macrophage phenotype	1668
M -LRB- IFN-γ -RRB-	1698
M	1698
IFN-γ	1700
M -LRB- IL-4 -RRB-	1710
M	1710
IL-4	1712
inflammatory cell infiltration in the injured site	1726
inflammatory cell infiltration	1726
the injured site	1760
inflammatory factors and chemokine expression , which provide a better immune environment for SCI repair	1791
inflammatory factors and chemokine expression	1791
a better immune environment for SCI repair	1852
a better immune environment	1852
SCI repair	1884
Keywords Olfactory ensheathing cells .	1896
Keywords	1896
Olfactory ensheathing cells	1905
Schwann cells .	1935
Spinal cord injury .	1951
Spinal cord	1951
injury	1963
Inflammatory response .	1972
Macrophage phenotypes Introduction Inflammatory responses following spinal cord injury -LRB- SCI -RRB- include	1996
Macrophage phenotypes	1996
Introduction Inflammatory responses following spinal cord injury -LRB- SCI -RRB-	2019
Introduction Inflammatory responses	2019
spinal cord injury -LRB- SCI -RRB-	2065
spinal cord injury	2065
SCI	2085
vascular permeability and extravasation	2108
large numbers of neutrophils and monocytes/macrophages	2151
large numbers	2151
neutrophils and monocytes/macrophages	2168
tissues	2211
the functions of these cells	2231
the functions	2231
these cells	2248
inflammatory factors	2289
The dynamic balance among inflammatory factors	2311
The dynamic balance	2311
inflammatory factors	2337
the activation of astrocytes and macrophages , which can exacerbate tissue damage or promote tissue repair -LSB- 1 , 2 -RSB-	2374
the activation	2374
astrocytes and macrophages , which can exacerbate tissue damage or promote tissue repair -LSB- 1 , 2 -RSB-	2392
astrocytes and macrophages	2392
tissue damage	2441
tissue repair	2466
-LSB- 1 , 2	2480
cell transplantation	2499
one of the most promising methods for the treatment of SCI	2523
one	2523
the most promising methods for the treatment of SCI	2530
the most promising methods	2530
the treatment of SCI	2561
the treatment	2561
SCI	2578
Previous reports of the use of donor cells including olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells -LRB- SCs -RRB- , bone marrow stromal cells , neural stem cells , and embryonic stem cells	2583
Previous reports	2583
the use of donor cells including olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells -LRB- SCs -RRB- , bone marrow stromal cells , neural stem cells , and embryonic stem cells	2603
the use	2603
donor cells including olfactory ensheathing cells -LRB- OECs -RRB- , Schwann cells -LRB- SCs -RRB- , bone marrow stromal cells , neural stem cells , and embryonic stem cells	2614
donor cells including olfactory ensheathing cells -LRB- OECs -RRB-	2614
donor cells	2614
olfactory ensheathing cells -LRB- OECs -RRB-	2636
olfactory ensheathing cells	2636
OECs	2665
Schwann cells -LRB- SCs -RRB-	2672
Schwann cells	2672
SCs	2687
bone marrow stromal cells	2693
bone marrow	2693
stromal cells	2705
neural stem cells	2720
embryonic stem cells	2743
limited success for this purpose	2779
limited success	2779
this purpose	2799
animal experiments -LSB- 3	2815
animal experiments	2815
3	2835
7 -RSB-	2837
Numerous studies	2841
OECs	2874
necrotic or apoptotic neural cells	2891
remyelination	2935
multiple neurotrophins -LSB- 8 , 9 -RSB-	2962
multiple neurotrophins	2962
8	2986
SCs	2993
basement membrane components including type IV collagen and laminin	3005
basement membrane components	3005
type IV collagen and laminin	3044
type IV collagen	3044
laminin	3065
axonal regeneration	3085
10 -RSB-	3106
It	3111
co-transplantation of OECs and SCs	3148
co-transplantation	3148
OECs and SCs	3170
motor function	3217
SCI -LSB- 11 , 12 -RSB-	3238
We	3251
this synergistic effect	3270
the regulation of inflammatory responses after SCI , in addition to the biological characteristics of the donor cell itself	3310
the regulation	3310
inflammatory responses after SCI , in addition to the biological characteristics of the donor cell itself	3328
inflammatory responses after SCI	3328
inflammatory responses	3328
SCI	3357
the biological characteristics of the donor cell itself	3377
the biological characteristics	3377
the donor cell itself	3411
the donor cell	3411
The inflammatory responses after SCI	3434
The inflammatory responses	3434
SCI	3467
a dynamic balance of the macrophage activation -LSB- 13 -RSB-	3502
a dynamic balance	3502
the macrophage activation -LSB- 13 -RSB-	3523
the macrophage activation	3523
13 -RSB-	3550
Macrophages activated by IFN-γ , as means of M -LRB- IFN-γ -RRB- ,	3555
Macrophages	3555
IFN-γ	3580
means of M -LRB- IFN-γ -RRB-	3590
means	3590
M -LRB- IFN-γ -RRB-	3599
M	3599
IFN-γ	3601
neurotoxic effects , while macrophages activated by IL-4 , as means of M -LRB- IL-4 -RRB- ,	3617
neurotoxic effects	3617
macrophages	3643
IL-4	3668
means of M -LRB- IL-4 -RRB-	3677
means	3677
M -LRB- IL-4 -RRB-	3686
M	3686
IL-4	3688
harmful immune responses	3707
damage repair	3751
-LSB- 14 , 15 -RSB-	3765
Only very few studies	3775
the regulatory effects of cell transplantation	3813
the regulatory effects	3813
cell transplantation	3839
phagocytes	3875
SCI -LSB- 16 -RSB-	3889
SCI -LSB-	3889
no study	3913
the synergistic effects of co-transplantation of two cell types	3959
the synergistic effects	3959
co-transplantation of two cell types	3986
co-transplantation	3986
two cell types	4008
regulation of macrophage activation following SCI	4026
regulation	4026
macrophage activation following SCI	4040
macrophage activation	4040
SCI	4072
the present study	4080
OECs and SCs	4099
the injured spinal cord	4138
the synergistic effects	4177
the local inflammation environment	4204
the histological changes in the injured spinal cord	4254
the histological changes	4254
the injured spinal cord	4282
The present results	4307
co-implantation of OECs and SCs	4339
co-implantation	4339
OECs and SCs	4358
expression levels of pro- and anti-inflammatory factors , which was followed by increased percentage of Arg	4393
expression levels	4393
pro- and anti-inflammatory factors , which was followed by increased percentage of Arg	4414
pro- and anti-inflammatory factors	4414
increased percentage of Arg	4472
increased percentage	4472
Arg	4496
CD206 + cells	4502
CD206	4502
cells	4509
percentage of iNOS + / CD16/32 + cells	4527
percentage	4527
iNOS + / CD16/32 + cells	4541
iNOS +	4541
iNOS	4541
+	4545
CD16/32 + cells	4547
CD16/32	4547
cells	4556
These effects	4563
the immune microenvironment	4591
the repair of local tissues	4628
the repair	4628
local tissues	4642
motor function of the contused rats	4669
motor function	4669
the contused rats	4687
Materials and Methods Animals	4707
All the animals	4737
the Third Military Medical University -LRB- TMMU -RRB- guidelines , and surgical procedures and post-operative care	4778
the Third Military Medical University -LRB- TMMU -RRB- guidelines	4778
TMMU	4817
surgical procedures and post-operative care	4839
surgical procedures	4839
post-operative care	4863
accordance	4901
protocols approved by the TMMU Institutional Animal Care and Use Committee	4917
protocols	4917
the TMMU Institutional Animal Care and Use Committee	4939
Preparation of OECs from Rats OECs	4993
Preparation	4993
OECs from Rats OECs	5008
OECs	5008
Rats OECs	5018
the olfactory bulbs of adult green fluorescent protein-transgenic -LRB- GFP-Tg -RRB- rats or Sprague Dawley -LRB- SD -RRB- rats	5048
the olfactory bulbs of adult green fluorescent protein-transgenic -LRB- GFP-Tg -RRB- rats	5048
the olfactory bulbs	5048
adult green fluorescent protein-transgenic -LRB- GFP-Tg -RRB- rats	5071
Sprague Dawley -LRB- SD -RRB- rats	5131
SD	5147
a previously described method -LSB- 17 -RSB-	5162
a previously described method	5162
17 -RSB-	5193
the caudal two thirds of the olfactory bulbs	5207
the caudal two thirds	5207
the olfactory bulbs	5232
meninges and white matter	5274
meninges	5274
white matter	5287
scalpel blades	5313
25 min in 0.125 % trypsin -LRB- Gibco , USA -RRB-	5347
25 min	5347
0.125 % trypsin -LRB- Gibco , USA -RRB-	5357
0.125 % trypsin	5357
Gibco	5374
USA	5381
37 °C in a 5 % CO2 incubator	5389
37 °C	5389
a 5 % CO2 incubator	5398
Tissue	5417
The cell suspension	5477
1 h in Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	5515
1 h	5515
Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	5522
Dulbecco 's modified Eagle medium	5522
Dulbecco 's	5522
DMEM	5556
F12 medium supplemented with 10 % fetal calf serum -LRB- FCS , Gibco , USA -RRB-	5562
F12 medium	5562
10 % fetal calf serum -LRB- FCS , Gibco , USA -RRB-	5591
10 % fetal calf serum	5591
FCS	5614
Gibco	5619
USA	5626
the non-adherent cells	5659
the cultures	5690
the same medium supplemented with 10 ng/ml basic fibroblast growth factor -LRB- bFGF -RRB- , and 2 μM forskolin -LRB- Sigma , USA -RRB-	5720
the same medium	5720
10 ng/ml basic fibroblast growth factor -LRB- bFGF -RRB- , and 2 μM forskolin -LRB- Sigma , USA -RRB-	5754
10 ng/ml basic fibroblast growth factor -LRB- bFGF -RRB-	5754
10 ng/ml	5754
basic fibroblast growth factor -LRB- bFGF -RRB-	5763
basic fibroblast growth factor	5763
bFGF	5795
2 μM forskolin -LRB- Sigma , USA -RRB-	5806
2 μM forskolin	5806
Sigma	5822
USA	5829
the cells	5840
confluence	5863
they	5875
the purity of OECs	5898
the purity	5898
OECs	5912
immunostaining of anti-S100 and anti-P75	5934
immunostaining	5934
anti-S100 and anti-P75	5952
Abcam , USA	5985
The OEC preparations	5998
> 95 %	6041
>	6041
S100 and p75	6061
a second passage	6081
the cells	6099
1.0 ×	6140
105 cells/μl for transplantation	6146
105 cells/μl	6146
transplantation	6163
Preparation of SCs from Rats SCs	6180
Preparation	6180
SCs from Rats SCs	6195
SCs	6195
Rats SCs	6204
the sciatic nerves of adult GFP-Tg rats or SD rats	6232
the sciatic nerves	6232
adult GFP-Tg rats or SD rats	6254
adult GFP-Tg rats	6254
SD rats	6275
18 -RSB-	6309
removal of the epineurium , connective tissue , and blood vessels	6333
removal	6333
the epineurium , connective tissue , and blood vessels	6344
the epineurium	6344
connective tissue	6360
blood vessels	6383
sciatic nerve explants	6398
approximately 1 mm3	6435
2 h in 1.25 U/ml dispase , 0.05 % collagenase , 15 % FCS , and 25 mM HEPES in DMEM -LRB- all from Gibco , USA -RRB-	6473
2 h	6473
1.25 U/ml dispase , 0.05 % collagenase , 15 % FCS , and 25 mM HEPES in DMEM -LRB- all from Gibco , USA -RRB-	6480
1.25 U/ml dispase	6480
0.05 % collagenase , 15 % FCS , and 25 mM HEPES in DMEM -LRB- all from Gibco , USA -RRB-	6499
0.05 % collagenase	6499
15 % FCS	6519
25 mM HEPES in DMEM -LRB- all from Gibco , USA -RRB-	6533
25 mM HEPES	6533
DMEM -LRB- all from Gibco , USA -RRB-	6548
DMEM	6548
all from Gibco , USA	6554
all	6554
Gibco , USA	6563
37 °C in a 5 % CO2 incubator	6578
37 °C	6578
a 5 % CO2 incubator	6587
the explants	6614
two to three times in DMEM and placed into 35-mm tissue culture dishes containing DMEM/10 % FCS -LRB- 750 μl/dish -RRB-	6639
two to three times in DMEM and placed into 35-mm tissue culture dishes containing DMEM/10 % FCS	6639
two to three times	6639
DMEM and placed into 35-mm tissue culture dishes containing DMEM/10 % FCS	6661
35-mm tissue culture dishes containing DMEM/10 %	6682
35-mm tissue culture dishes	6682
DMEM/10 %	6721
750 μl/dish	6736
the outgrowth around the explants	6755
the outgrowth	6755
the explants	6776
a near-confluent monolayer -LRB- 7 -- 10 days -RRB-	6797
a near-confluent monolayer	6797
7 -- 10 days	6825
7	6825
10 days	6827
the explants	6837
new dishes	6870
fresh medium	6892
this process	6906
4 -- 5 weeks	6937
4	6937
5 weeks	6939
this time	6951
the outgrowth	6962
SCs	6996
The explants	7001
enzymatic digestion	7041
the cells	7102
confluence	7125
they	7137
the purity of SCs	7160
the purity	7160
SCs	7174
immunostaining of anti-S100 -LRB- Abcam , USA -RRB-	7195
immunostaining	7195
anti-S100 -LRB- Abcam , USA -RRB-	7213
anti-S100	7213
Abcam	7224
USA	7231
At least 80 % of the cells	7237
At least 80 %	7237
the cells	7252
S100	7286
The cells	7292
1.0 ×	7333
105 cells/μl for transplantation	7339
105 cells/μl	7339
transplantation	7356
Animal Model of Spinal Cord Injury Adult female SD rats -LRB- 200 -- 250 g -RRB-	7373
Animal Model of Spinal Cord Injury Adult female SD rats	7373
Animal Model	7373
Spinal Cord Injury Adult female SD rats	7389
200 -- 250 g	7430
200	7430
250 g	7434
a single intraperitoneal injection of 1 % sodium pentobarbiturate -LRB- 30 mg/kg -RRB-	7464
a single intraperitoneal injection	7464
1 % sodium pentobarbiturate -LRB- 30 mg/kg -RRB-	7502
1 % sodium pentobarbiturate	7502
30 mg/kg	7531
A sterile laminectomy	7542
the vertebral T10 level	7581
the dura	7624
The spinal cord	7634
an NYU-II impactor	7669
a weight of 10.0 g released from 25 mm above the exposed cord	7693
a weight	7693
10.0 g released from 25 mm above the exposed cord	7705
10.0 g	7705
25 mm above the exposed cord	7726
25 mm	7726
the exposed cord	7738
injury	7762
the muscles and skin	7770
the muscles	7770
skin	7786
layers	7806
The procedure	7814
hind limb paralysis	7840
all the animals	7863
Bicillin -LRB- 60,000 U/kg , intramuscular route -RRB-	7880
Bicillin	7880
60,000 U/kg , intramuscular route	7890
60,000 U/kg	7890
intramuscular route	7903
7 days after contusion	7951
7 days	7951
contusion	7964
wound and bladder infections	7985
bladder expression performed twice daily	8020
bladder expression	8020
Cell Transplantation Cell transplantation	8062
Cell Transplantation	8062
Cell transplantation	8083
the seventh day	8121
spinal cord injury using a previously described method -LSB- 17 -RSB-	8143
spinal cord injury	8143
a previously described method -LSB- 17 -RSB-	8168
a previously described method	8168
17 -RSB-	8199
rats	8213
the laminectomy site	8240
Cell suspensions -LRB- 1.0 × 105 cells/μl for SCs , OECs , or SCs + OECs -RRB-	8277
Cell suspensions	8277
1.0 × 105 cells/μl for SCs , OECs , or SCs + OECs	8295
1.0 ×	8295
105 cells/μl for SCs , OECs , or SCs + OECs	8301
105 cells/μl	8301
SCs , OECs , or SCs + OECs	8318
SCs	8318
OECs	8323
SCs + OECs	8332
OECs	8336
a surgical microscope using a Hamilton syringe , which remained in place for 5 min after each injection	8362
a surgical microscope	8362
a Hamilton syringe , which remained in place for 5 min after each injection	8390
a Hamilton syringe	8390
place for 5 min	8428
place	8428
5 min	8438
each injection	8450
Cells	8466
the midline of the contused cord at a depth of 0.8 mm at the epicenter of the lesion and at 1 mm rostral and caudal to the epicenter -LRB- 2 μl per injection ; a total of 6 μl of cell suspension was used -RRB-	8492
the midline of the contused cord at a depth of 0.8 mm at the epicenter of the lesion and at 1 mm rostral	8492
the midline	8492
the contused cord at a depth of 0.8 mm at the epicenter of the lesion and at 1 mm rostral	8507
cord	8520
a depth of 0.8 mm	8528
a depth	8528
0.8 mm	8539
the epicenter of the lesion	8549
the epicenter	8549
the lesion	8566
1 mm	8584
caudal to the epicenter -LRB- 2 μl per injection ; a total of 6 μl of cell suspension was used -RRB-	8601
caudal to the epicenter	8601
caudal	8601
the epicenter	8611
2 μl per injection	8626
2 μl	8626
injection	8635
a total of 6 μl of cell suspension	8646
a total	8646
6 μl of cell suspension	8657
6 μl	8657
cell suspension	8665
co-transplantation of SCs and OECs	8696
co-transplantation	8696
SCs and OECs	8718
the 1:1 proportion	8732
mixed suspension of 3 μl SCs and 3 μl OECs	8761
mixed suspension	8761
3 μl SCs and 3 μl OECs	8781
3 μl SCs	8781
3 μl OECs	8794
Control animals	8806
identical volumes of DMEM	8841
identical volumes	8841
DMEM	8862
the same sites	8870
the injection	8892
the muscle and skin	8907
interrupted sutures	8944
The migration and the distribution of transplanted cells	8965
The migration	8965
the distribution of transplanted cells	8983
the distribution	8983
transplanted cells	9003
five longitudinal sections selected from every fifth serial section and prepared from the five host cords selected at random from each group	9040
five longitudinal sections	9040
every fifth serial section	9081
the five host cords selected at random from each group	9126
the five host cords	9126
each group	9170
The digital images	9182
× 20	9219
Adobe Photoshop 10.0	9241
measurements	9276
The total migration distance	9290
the longitudinal axis of the host cord and the total distribution area of the fluorescence cells within the cord	9330
the longitudinal axis of the host cord	9330
the longitudinal axis	9330
the host cord	9355
the total distribution area of the fluorescence cells within the cord	9373
the total distribution area	9373
the fluorescence cells within the cord	9404
the fluorescence cells	9404
the cord	9434
Image	9462
Pro Plus 6.0 -LRB- Media Cybemetics Inc. , Silver Spring , USA -RRB-	9468
Pro	9468
6.0	9477
Media Cybemetics Inc. , Silver Spring , USA	9482
Media Cybemetics Inc.	9482
Silver Spring	9505
USA	9520
Tissue Processing and Histopathology The spinal cord	9526
Tissue Processing	9526
Histopathology The spinal cord	9548
Histopathology	9548
The spinal cord	9563
4 % paraformaldehyde	9607
the same fixative for 24 h	9646
the same fixative	9646
24 h	9668
then overnight in 30 % sucrose	9674
then overnight	9674
30 % sucrose	9692
1 week after transplantation	9708
1 week	9708
transplantation	9721
Segments of the spinal cord centered on the impact site	9738
Segments	9738
the spinal cord centered on the impact site	9750
the spinal cord	9750
the impact site	9778
optimal cutting temperature compound -LRB- OCT -RRB-	9811
optimal cutting temperature compound	9811
OCT	9849
serial 10-μm-thick sagittal sections on a cryostat -LRB- Leica -RRB-	9864
serial 10-μm-thick sagittal sections	9864
a cryostat -LRB- Leica -RRB-	9904
a cryostat	9904
Leica	9916
histopathology	9927
− 70 °C -LRB- n = 3 rats / group -RRB-	9957
− 70 °C	9957
n = 3 rats / group	9965
n	9965
= 3 rats / group	9966
= 3 rats	9966
3	9968
group	9976
Slides	9984
PBS for 10 min	10020
PBS	10020
10 min	10028
The sections	10036
0.3 % Triton X-100	10073
0.3 %	10073
Triton X-100	10079
10 % normal goat serum	10109
0.01 M PBS for 2 h. Sections	10135
0.01 M PBS	10135
2 h. Sections	10150
overnight at 4 °C	10184
overnight	10184
4 °C	10197
polyclonal rabbit	10207
anti-glial fibrillary acidic protein -LRB- GFAP , 1:3000 -RRB- for astrocytes , mouse anti-Iba1 -LRB- 1:100 -RRB- for microglias/macrophages , rabbit anti-iNOS -LRB- 1:100 -RRB- and mouse anti-CD16 / 32 -LRB- 1:200 -RRB- for M -LRB- IFN-γ -RRB- , and rabbit anti-arginase-1 -LRB- 1:500 -RRB- and mouse anti-CD206 -LRB- 1:1000 ; all from Abcam , Cambridge , MA , USA -RRB- for M -LRB- IL-4 -RRB-	10225
anti-glial fibrillary acidic protein -LRB- GFAP , 1:3000 -RRB- for astrocytes	10225
anti-glial fibrillary acidic protein -LRB- GFAP , 1:3000 -RRB-	10225
anti-glial fibrillary acidic protein	10225
GFAP , 1:3000	10263
GFAP	10263
1:3000	10269
astrocytes	10281
mouse anti-Iba1 -LRB- 1:100 -RRB- for microglias/macrophages , rabbit anti-iNOS -LRB- 1:100 -RRB- and mouse anti-CD16 / 32 -LRB- 1:200 -RRB- for M -LRB- IFN-γ -RRB-	10293
mouse anti-Iba1 -LRB- 1:100 -RRB-	10293
mouse anti-Iba1	10293
1:100	10310
microglias/macrophages	10321
rabbit anti-iNOS -LRB- 1:100 -RRB-	10345
rabbit anti-iNOS	10345
1:100	10363
mouse anti-CD16 / 32 -LRB- 1:200 -RRB- for M -LRB- IFN-γ -RRB-	10374
mouse anti-CD16 / 32 -LRB- 1:200 -RRB- for M	10374
mouse anti-CD16	10374
32 -LRB- 1:200 -RRB- for M	10390
32 -LRB- 1:200 -RRB-	10390
32	10390
1:200	10394
M	10405
IFN-γ	10407
rabbit anti-arginase-1 -LRB- 1:500 -RRB- and mouse anti-CD206 -LRB- 1:1000 ; all from Abcam , Cambridge , MA , USA -RRB- for M -LRB- IL-4 -RRB-	10420
rabbit anti-arginase-1 -LRB- 1:500 -RRB-	10420
rabbit anti-arginase-1	10420
1:500	10444
mouse anti-CD206 -LRB- 1:1000 ; all from Abcam , Cambridge , MA , USA -RRB- for M -LRB- IL-4 -RRB-	10455
mouse anti-CD206 -LRB- 1:1000 ; all from Abcam , Cambridge , MA , USA -RRB-	10455
mouse anti-CD206	10455
1:1000 ; all from Abcam , Cambridge , MA , USA	10473
1:1000	10473
all from Abcam , Cambridge , MA , USA	10481
all from Abcam , Cambridge , MA ,	10481
all	10481
Abcam , Cambridge , MA ,	10490
USA	10512
M -LRB- IL-4 -RRB-	10521
M	10521
IL-4	10523
immunohistochemical staining	10534
the sections	10564
HRP-conjugated secondary antibodies -LRB- 1:200 ; Abcam , USA -RRB- for 2 h	10597
HRP-conjugated secondary antibodies -LRB- 1:200 ; Abcam , USA -RRB-	10597
HRP-conjugated secondary antibodies	10597
1:200 ; Abcam , USA	10634
1:200	10634
Abcam , USA	10641
2 h	10657
room temperature	10664
incubation for 5 min with 0.02 % DAB	10688
incubation	10688
5 min with 0.02 % DAB	10703
5 min	10703
0.02 % DAB	10714
0.02 %	10714
DAB	10721
the sections	10726
hematoxylin	10764
immunofluorescence staining	10781
the sections	10810
anti-mouse TRITC-conjugated antibody -LRB- 1:200 ; Beyotime , People 's Republic of China -RRB- and anti-rabbit FITC-conjugated antibody -LRB- 1:200 ; Beyotime , People 's Republic of China -RRB-	10843
anti-mouse TRITC-conjugated antibody	10843
1:200 ; Beyotime	10881
1:200	10881
Beyotime	10888
People 's Republic of China	10898
People 's Republic	10898
People 's	10898
China	10919
anti-rabbit FITC-conjugated antibody	10930
1:200 ; Beyotime	10968
1:200	10968
Beyotime	10975
People 's Republic of China	10985
People 's Republic	10985
People 's	10985
China	11006
2 h at room temperature	11017
2 h	11017
room temperature	11024
Nuclei	11042
Hoechst33342 -LRB- 5 μg/ml ; Beyotime , People 's Republic of China -RRB-	11067
Hoechst33342	11067
5 μg/ml ; Beyotime	11081
5 μg/ml	11081
Beyotime	11090
People 's Republic of China	11100
People 's Republic	11100
People 's	11100
China	11121
Five sections	11129
every fifth serial section	11162
three animals	11207
each group	11221
The images	11233
20 ×	11265
Adobe Photoshop 10.0	11287
Areas of positive immunoreactivity	11309
Areas	11309
positive immunoreactivity	11318
Image	11361
Pro Plus 6.0	11367
Pro	11367
6.0	11376
The proportion of the GFAP and Iba1 positive areas	11381
The proportion	11381
the GFAP and Iba1 positive areas	11399
the GFAP	11399
Iba1 positive areas	11412
a percentage of DMEM group	11464
a percentage	11464
DMEM group	11480
The number of iNOS + / CD16/32 + cells and arginase-1 + / CD206 + cells	11492
The number of iNOS + / CD16/32 + cells and arginase-1 + /	11492
The number	11492
iNOS + / CD16/32 + cells and arginase-1 + /	11506
iNOS +	11506
iNOS	11506
+	11510
CD16/32 + cells and arginase-1	11512
CD16/32 + cells	11512
arginase-1	11531
+	11541
CD206 + cells	11543
a permillage of the total cells -LRB- blue fluorescence -RRB- in five sections	11585
a permillage	11585
the total cells -LRB- blue fluorescence -RRB- in five sections	11601
the total cells -LRB- blue fluorescence -RRB-	11601
the total cells	11601
blue fluorescence	11618
five sections	11640
Histological Assessment HE staining	11655
Histological Assessment	11655
HE staining	11679
allowmeasurement of area of the cystic cavities within spinal cord sections	11708
allowmeasurement	11708
area of the cystic cavities within spinal cord sections	11728
area	11728
the cystic cavities within spinal cord sections	11736
the cystic cavities	11736
spinal cord sections	11763
6 weeks	11787
transplantation	11801
Five longitudinal sections of the injury epicenter from each animal	11818
Five longitudinal sections	11818
the injury epicenter from each animal	11848
the injury epicenter	11848
each animal	11874
every fifth serial section -LRB- n = 6/group -RRB-	11905
every fifth serial section	11905
n = 6/group	11933
n	11933
= 6/group	11934
The digital images	11945
× 20	11981
an Olympus CCD camera	11991
Adobe Photoshop 10.0	12031
The total area of cavities	12053
The total area	12053
cavities	12071
Image	12099
Pro Plus 6.0	12105
Pro	12105
6.0	12114
Media Cybemetics Inc. , Silver Spring ,	12120
Media Cybemetics Inc.	12120
Silver Spring	12143
Western Blotting Spinal cord segments 5 mm long centered on the injury epicenter	12164
Western Blotting Spinal cord segments	12164
5 mm	12202
the injury epicenter	12224
1	12262
week	12264
transplantation	12275
Total proteins	12292
a total protein extracted kit -LRB- keygen , People 's Republic of China -RRB- according to the kit manufacturer 's recommended protocol and subjected to SDS PAGE -LRB- 12 % gels ; n = 3/group -RRB-	12328
a total protein	12328
kit -LRB- keygen , People 's Republic of China -RRB-	12354
kit	12354
keygen , People 's Republic of China	12359
keygen	12359
People 's Republic of China	12367
People 's Republic	12367
People 's	12367
China	12388
the kit manufacturer 's recommended protocol	12408
the kit manufacturer 's	12408
SDS PAGE -LRB- 12 % gels ; n = 3/group -RRB-	12469
SDS PAGE	12469
12 % gels ; n = 3/group	12479
12 % gels	12479
n = 3/group	12488
Western blotting	12500
standard techniques	12537
equal amounts of protein loaded into each well	12563
equal amounts	12563
protein loaded into each well	12580
protein	12580
each	12600
The membranes	12611
GFAP -LRB- 1:30,000 -RRB- , Iba1 -LRB- 1:1000 -RRB- , interleukin-4 -LRB- IL-4 , 1:3000 -RRB- , interferon-gamma -LRB- IFN-γ , 1:3000 -RRB- , tumor necrosis factor-α -LRB- TNF-α , 1:800 -RRB- , interleukin-6 -LRB- IL-6 , 1:1000 -RRB- , interleukin-10 -LRB- IL-10 , 1:1000 -RRB- , interleukin-13 -LRB- IL-13 , 1:1000 -RRB- , chemokine ligand 2 -LRB- CCL2 , 1:2000 -RRB- , chemokine ligand 3 -LRB- CCL3 , 1:2000 -RRB- , and β-actin -LRB- 1:6000 -RRB-	12641
GFAP -LRB- 1:30,000 -RRB-	12641
GFAP	12641
1:30,000	12647
Iba1 -LRB- 1:1000 -RRB- , interleukin-4 -LRB- IL-4 , 1:3000 -RRB- , interferon-gamma -LRB- IFN-γ , 1:3000 -RRB- , tumor necrosis factor-α -LRB- TNF-α , 1:800 -RRB- , interleukin-6 -LRB- IL-6 , 1:1000 -RRB- , interleukin-10 -LRB- IL-10 , 1:1000 -RRB- , interleukin-13 -LRB- IL-13 , 1:1000 -RRB- , chemokine ligand 2 -LRB- CCL2 , 1:2000 -RRB- , chemokine ligand 3 -LRB- CCL3 , 1:2000 -RRB- , and β-actin -LRB- 1:6000 -RRB-	12658
Iba1 -LRB- 1:1000 -RRB-	12658
Iba1	12658
1:1000	12664
interleukin-4 -LRB- IL-4 , 1:3000 -RRB-	12673
interleukin-4	12673
IL-4 , 1:3000	12688
IL-4	12688
1:3000	12694
interferon-gamma -LRB- IFN-γ , 1:3000 -RRB-	12703
interferon-gamma	12703
IFN-γ , 1:3000	12721
IFN-γ	12721
1:3000	12728
tumor necrosis factor-α -LRB- TNF-α , 1:800 -RRB-	12737
tumor necrosis factor-α	12737
TNF-α , 1:800	12762
TNF-α	12762
1:800	12769
interleukin-6 -LRB- IL-6 , 1:1000 -RRB-	12777
interleukin-6	12777
IL-6 , 1:1000	12792
IL-6	12792
1:1000	12798
interleukin-10 -LRB- IL-10 , 1:1000 -RRB-	12807
interleukin-10	12807
IL-10 , 1:1000	12823
IL-10	12823
1:1000	12830
interleukin-13 -LRB- IL-13 , 1:1000 -RRB-	12839
interleukin-13	12839
IL-13 , 1:1000	12855
IL-13	12855
1:1000	12862
chemokine ligand 2 -LRB- CCL2 , 1:2000 -RRB-	12871
chemokine ligand 2	12871
chemokine ligand	12871
2	12888
CCL2 , 1:2000	12891
CCL2	12891
1:2000	12897
chemokine ligand 3 -LRB- CCL3 , 1:2000 -RRB-	12906
chemokine ligand 3	12906
chemokine ligand	12906
3	12923
CCL3 , 1:2000	12926
CCL3	12926
1:2000	12932
β-actin -LRB- 1:6000 -RRB-	12945
β-actin	12945
1:6000	12954
The intensity of immunostaining	12963
The intensity	12963
immunostaining	12980
HRP-conjugated secondary antibodies -LRB- all from Abcam , USA -RRB- and a commercially available kit for enhanced chemiluminescence -LRB- ECL ; Amersham , USA -RRB-	13016
HRP-conjugated secondary antibodies -LRB- all from Abcam , USA -RRB-	13016
HRP-conjugated secondary antibodies	13016
all from Abcam , USA	13053
all	13053
Abcam , USA	13062
a commercially available kit for enhanced chemiluminescence -LRB- ECL ; Amersham , USA -RRB-	13078
a commercially available kit	13078
enhanced chemiluminescence -LRB- ECL ; Amersham , USA -RRB-	13111
enhanced chemiluminescence	13111
ECL ; Amersham , USA	13139
ECL	13139
Amersham , USA	13144
All Western blots	13160
a chemiluminescence system -LRB- GE Healthcare , UK -RRB-	13199
a chemiluminescence system	13199
GE Healthcare	13227
UK	13242
data	13251
Quantity One 4.2.1 software -LRB- Bio-Rad , USA -RRB-	13276
Quantity One 4.2.1 software	13276
Quantity One	13276
4.2.1 software	13289
Bio-Rad	13305
USA	13314
The intensity of each band	13320
The intensity	13320
each band	13337
that of β-actin	13373
that	13373
β-actin	13381
Enzyme-Linked Immunosorbent Assay Commercially available	13390
Enzyme-Linked Immunosorbent Assay	13390
sandwich enzyme-linked immunosorbent assay -LRB- ELISA -RRB- kits were used to detect protein expression of the following cytokines : IL-4 and IFN-γ -LRB- all from Abcam , USA -RRB- known to modulate inflammation and neuroplasticity in the spinal cord and the chemokines CCL2 and CCL3	13447
sandwich enzyme-linked immunosorbent assay	13447
ELISA	13491
kits	13498
protein expression of the following cytokines : IL-4 and IFN-γ -LRB- all from Abcam , USA -RRB- known to modulate inflammation and neuroplasticity in the spinal cord and the chemokines CCL2 and CCL3	13523
protein expression of the following cytokines	13523
protein expression	13523
the following cytokines	13545
IL-4 and IFN-γ -LRB- all from Abcam , USA -RRB- known to modulate inflammation and neuroplasticity in the spinal cord and the chemokines CCL2 and CCL3	13570
IL-4 and IFN-γ -LRB- all from Abcam , USA -RRB-	13570
IL-4 and IFN-γ	13570
all from Abcam , USA	13586
all	13586
Abcam , USA	13595
inflammation and neuroplasticity	13625
the spinal cord and the chemokines CCL2 and CCL3	13661
the spinal cord	13661
the chemokines CCL2 and CCL3	13681
all fromYuanyanbio , People 's Republic of China	13711
all fromYuanyanbio	13711
People 's Republic of China	13731
People 's Republic	13731
People 's	13731
China	13752
The spinal cord segments 5 mm long centered on the epicenter	13760
The spinal cord segments	13760
5 mm	13785
the epicenter	13807
1	13838
week	13840
transplantation -LRB- n = 3 / group -RRB-	13851
transplantation	13851
n = 3 / group	13868
n	13868
= 3 / group	13869
= 3	13869
group	13873
Pre-cooling PBS -LRB- 1 ml -RRB-	13881
Pre-cooling PBS	13881
1 ml	13898
tissue homogenization	13918
an electric homogenizer -LRB- FSH-2 , People 's Republic of China -RRB-	13945
an electric homogenizer	13945
FSH-2 , People 's Republic of China	13970
FSH-2	13970
People 's Republic of China	13977
People 's Republic	13977
People 's	13977
China	13998
homogenates	14010
20,000 × g , 4 °C	14045
20,000 × g	14045
4 °C	14055
30 min	14064
The supernatant	14073
ELISA analysis	14107
the kit manufacturer 's recommended protocol	14135
the kit manufacturer 's	14135
The optical density of each well	14180
The optical density	14180
each well	14203
a microplate reader -LRB- Molecular Devices SpectraMax M5 -RRB-	14234
a microplate reader	14234
Molecular Devices SpectraMax M5	14255
Molecular Devices	14255
SpectraMax M5	14273
450 nm	14291
Assessment of Locomotor Behavior Using the Basso-Beattie-Bresnahan -LRB- BBB -RRB- locomotor rating scale -LSB- 19 -RSB- , all the rats were tested for locomotor function by two observers	14299
Assessment	14299
Locomotor Behavior Using the Basso-Beattie-Bresnahan -LRB- BBB -RRB- locomotor rating scale -LSB- 19 -RSB- , all the rats were tested for locomotor function by two observers	14313
Locomotor Behavior	14313
the Basso-Beattie-Bresnahan -LRB- BBB -RRB- locomotor rating scale -LSB- 19 -RSB- , all the rats were tested for locomotor function by two observers	14338
the Basso-Beattie-Bresnahan -LRB- BBB -RRB- locomotor rating scale	14338
Basso-Beattie-Bresnahan -LRB- BBB -RRB-	14342
Basso-Beattie-Bresnahan	14342
BBB	14367
19 -RSB-	14396
all the rats	14401
locomotor function	14430
two observers	14452
the treatment groups	14477
BBB testing	14499
the day of spinal cord injury	14538
the day	14538
spinal cord injury	14549
6 weeks	14571
Somatosensory Evoked	14601
Potential Recording and Analysis	14622
6 weeks	14658
transplantation	14672
12 rats -LRB- n = 3 in each group -RRB-	14689
12 rats	14689
n = 3 in each group	14698
n = 3	14698
n	14698
3	14701
each group	14706
3 % sodium pentobarbiturate , fixed stereotaxically , and injected with atropine sulfate -LRB- 0.8 mg/kg -RRB- for reducing tracheal secretions	14741
3 % sodium pentobarbiturate	14741
atropine sulfate -LRB- 0.8 mg/kg -RRB-	14811
atropine sulfate	14811
0.8 mg/kg	14829
tracheal secretions	14853
Sciatic nerves	14874
a bipolar platinum wire electrode with positive current pulses of 5 mA magnitude , 2 ms duration , and 4 Hz frequency	14924
a bipolar platinum wire electrode with positive current pulses of 5 mA magnitude	14924
a bipolar platinum wire electrode	14924
positive current pulses of 5 mA magnitude	14963
positive current pulses	14963
5 mA magnitude	14990
2 ms duration	15006
2 ms	15006
duration	15011
4 Hz frequency	15025
Somatosensory	15041
potential -LRB- SEP -RRB-	15062
potential	15062
SEP	15073
a Neuropack -LRB- Nihon Kohden Co , Japan -RRB- with a monopolar silver ball placed on the surface of the sensorimotor cortex -LRB- bregma − 2 mm , lateral 2 mm -RRB-	15099
a Neuropack -LRB- Nihon Kohden Co , Japan -RRB-	15099
a Neuropack	15099
Nihon Kohden Co	15112
Japan	15129
a monopolar silver ball placed on the surface of the sensorimotor cortex	15141
a monopolar silver ball	15141
the surface of the sensorimotor cortex	15175
the surface	15175
the sensorimotor cortex	15190
bregma − 2 mm , lateral 2 mm	15215
bregma −	15215
2 mm , lateral 2 mm	15223
2 mm	15223
lateral 2 mm	15229
2	15237
The effect of electrical stimulation on SEP	15244
The effect	15244
electrical stimulation on SEP	15258
electrical stimulation	15258
SEP	15284
terms of latency and amplitude	15304
terms	15304
latency and amplitude	15313
Statistical Analysis All values	15336
Statistical Analysis	15336
All values	15357
mean ± standard deviation	15385
Statistical differences	15412
one-way factorial analysis of variance -LRB- ANOVA -RRB-	15458
one-way factorial analysis	15458
variance -LRB- ANOVA -RRB-	15488
variance	15488
ANOVA	15498
Fisher 's least significant different -LRB- LSD -RRB- post hoc analysis	15509
Fisher 's least significant different -LRB- LSD -RRB-	15509
Fisher 's least significant different	15509
Fisher 's	15509
LSD	15547
post hoc analysis	15552
a P value	15571
statistical significance	15595
All statistical analyses	15621
SPSS software version	15667
17.0 -LRB- SPSS Inc. , Chicago , IL , USA -RRB-	15689
17.0	15689
SPSS Inc. , Chicago , IL , USA	15695
SPSS Inc.	15695
Chicago	15706
IL	15715
USA	15719
Results Table 1 Area and distribution of transplanted cells in the injured spinal cord Fig. 1 Migration and distribution of GFP-OECs and/or GFP-SCs in the injured spinal cord at 1 week and 6 weeks after transplantation .	15726
Results Table 1	15726
Results	15726
Table 1	15734
Area and distribution of transplanted cells in the injured spinal cord Fig.	15742
Area	15742
distribution of transplanted cells in the injured spinal cord Fig.	15751
distribution	15751
transplanted cells in the injured spinal cord Fig.	15767
transplanted cells	15767
the injured spinal cord Fig.	15789
1	15819
Migration and distribution of GFP-OECs and/or GFP-SCs in the injured spinal cord at 1 week and 6 weeks	15821
Migration and distribution	15821
GFP-OECs and/or GFP-SCs in the injured spinal cord at 1 week and 6 weeks	15851
GFP-OECs and/or GFP-SCs	15851
the injured spinal cord at 1 week and 6 weeks	15878
the injured spinal cord	15878
1 week and 6 weeks	15905
1 week	15905
6 weeks	15916
transplantation	15930
The migration distance of the donor cells in the SC + OEC cotransplantation group	15947
The migration distance	15947
the donor cells in the SC + OEC cotransplantation group	15973
the donor cells	15973
the SC + OEC cotransplantation group	15992
the SC	15992
OEC cotransplantation group	16000
the distribution	16044
that in the other groups	16085
that	16085
the other groups	16093
6 weeks	16113
Scale bar = 200 μm Fig. 2 SC + OEC cotransplantation	16143
Scale	16143
= 200 μm Fig. 2 SC + OEC cotransplantation	16152
= 200 μm Fig. 2 SC	16152
OEC cotransplantation	16172
astrocyte and microglia/macrophage infiltration of the injured spinal cord	16202
astrocyte and microglia/macrophage infiltration	16202
the injured spinal cord	16253
1 week post-transplantation	16280
GFAP and Iba1 expression levels	16309
SC + OEC co-transplantation	16367
SC	16367
OEC co-transplantation	16371
that in the DMEM , SC , and OEC groups evaluated by immunohistochemical staining -LRB- a , c -RRB- orWestern blotting analysis -LRB- b , d -RRB-	16408
that	16408
the DMEM , SC , and OEC groups	16416
immunohistochemical staining -LRB- a , c -RRB- orWestern blotting analysis -LRB- b , d -RRB-	16458
immunohistochemical staining -LRB- a , c -RRB-	16458
immunohistochemical staining	16458
a , c	16488
a	16488
c	16491
orWestern blotting analysis -LRB- b , d -RRB-	16494
orWestern blotting analysis	16494
Scale	16530
50 μm	16540
P <	16549
P	16549
<	16550
0.05	16551
P	16560
0.01 Fig. 3 Expression of cytokines -LRB- IL-4 and IFN-γ -RRB- and chemokines -LRB- CCL2 and CCL3 -RRB- in the spinal cord at 1 week after cell transplantation	16562
0.01 Fig.	16562
3 Expression	16573
cytokines -LRB- IL-4 and IFN-γ -RRB- and chemokines -LRB- CCL2 and CCL3 -RRB-	16589
cytokines	16589
IL-4 and IFN-γ	16600
IL-4	16600
IFN-γ	16609
chemokines	16620
CCL2 and CCL3	16632
CCL2	16632
CCL3	16641
the spinal cord	16650
1 week after cell transplantation	16669
1 week	16669
cell transplantation	16682
the SC + OEC co-transplantation group	16707
the SC	16707
OEC co-transplantation group	16716
IFN-γ , CCL2 , and CCL3 levels	16746
those of the DMEM , SC , and OEC groups	16812
those	16812
the DMEM , SC , and OEC groups	16821
the IL-4 level	16859
Western blotting analysis -LRB- a , b -RRB- or ELISA analysis -LRB- c -RRB-	16902
Western blotting analysis	16902
a , b	16929
a	16929
b	16932
ELISA analysis	16938
c	16954
One asterisk P < 0.05 , two asterisks	16958
One asterisk P	16958
< 0.05 , two asterisks	16972
<	16972
0.05 , two asterisks	16973
P	16993
< 0.01 Fig.	16994
<	16994
0.01 Fig.	16995
4 Immunofluorescence staining	17006
differences	17043
the expression of iNOS and CD16/32	17058
the expression	17058
iNOS and CD16/32	17076
markers of IFN-γ-induced macrophages , and arginase-1 and CD206 as markers of IL-4	17096
markers of IFN-γ-induced macrophages	17096
markers	17096
IFN-γ-induced macrophages	17107
arginase-1 and CD206 as markers of IL-4	17138
arginase-1 and CD206	17138
markers of IL-4	17162
markers	17162
IL-4	17173
macrophages	17187
1 week post-transplantation	17203
the SC + OEC co-transplantation group	17235
the SC	17235
OEC co-transplantation group	17243
the number of iNOS + / CD16/32 + cells decreased , and the number of arginase-1 + / CD206 + cells	17273
the number of iNOS +	17273
the number	17273
iNOS +	17287
iNOS	17287
+	17291
CD16/32 + cells decreased , and the number of arginase-1 +	17294
CD16/32 + cells	17294
the number	17324
arginase-1	17338
+	17348
CD206 + cells	17351
those in the DMEM , SC , and OEC groups -LRB- P < 0.05 -RRB-	17386
those	17386
the DMEM , SC , and OEC groups	17395
P < 0.05	17425
P	17425
< 0.05	17426
<	17426
0.05	17427
Scale	17434
= 100 μm Fig. 5 Expression of pro-inflammatory factors -LRB- IL-6 and TNF-α -RRB- and anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	17443
= 100 μm Fig. 5 Expression	17443
pro-inflammatory factors -LRB- IL-6 and TNF-α -RRB- and anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	17473
pro-inflammatory factors	17473
IL-6 and TNF-α	17499
IL-6	17499
TNF-α	17508
anti-inflammatory factors	17519
IL-10 and IL-13	17546
IL-10	17546
IL-13	17556
the spinal cord at 1 week after cell transplantation	17566
the spinal cord	17566
1 week after cell transplantation	17585
1 week	17585
cell transplantation	17598
those of the DMEM , SC , and OEC groups	17634
those	17634
the DMEM , SC , and OEC groups	17643
the levels of IL-6 and TNF-α in the SC + OEC cotransplantation group	17673
the levels	17673
IL-6 and TNF-α in the SC + OEC cotransplantation group	17687
IL-6 and TNF-α	17687
the SC + OEC cotransplantation group	17705
the SC	17705
OEC cotransplantation group	17714
the levels of IL-10 and IL-13	17774
the levels	17774
IL-10 and IL-13	17788
One asterisk P < 0.05 , two asterisks P < 0.01 Fig. 6 Co-transplantation of OECs and SCs reduced the area of cystic cavities induced by SCI at 6 weeks after cell transplantation .	17834
One asterisk P	17834
0.05 , two asterisks P < 0.01 Fig. 6 Co-transplantation of OECs and SCs	17851
0.05	17851
two asterisks P <	17857
two asterisks	17857
P <	17871
P	17871
<	17872
0.01 Fig.	17873
6 Co-transplantation of OECs and SCs	17884
6 Co-transplantation	17884
OECs and SCs	17908
the area of cystic cavities induced by SCI	17929
the area	17929
cystic cavities induced by SCI	17941
cystic cavities	17941
SCI	17968
6 weeks	17975
cell transplantation	17989
Scale	18011
1 cm	18021
the photographs of the injured spinal cord	18029
the photographs	18029
the injured spinal cord	18048
Scale	18073
1 mm	18083
the micrographs	18091
The histogram	18108
the area of cystic cavities	18126
the area	18126
cystic cavities	18138
the injury epicenter in each group at 6 weeks after SCI	18157
the injury epicenter	18157
each group at 6 weeks after SCI	18181
each group	18181
6 weeks after SCI	18195
6 weeks	18195
SCI	18209
One asterisk P < 0.05 , two asterisks	18214
One asterisk P	18214
<	18229
0.05 , two asterisks	18231
0.05	18231
two asterisks	18237
P <	18251
0.01 Fig. 7 Changes in BBB scores	18253
0.01 Fig. 7 Changes	18253
BBB scores	18277
the day of spinal cord injury to 6 weeks after cell transplantation	18293
the day	18293
spinal cord injury to 6 weeks after cell transplantation	18304
spinal cord injury	18304
6 weeks after cell transplantation	18326
6 weeks	18326
cell transplantation	18340
A significant improvement in hindlimb motor function	18362
A significant improvement	18362
hindlimb motor function	18391
the SC + OEC cotransplantation group	18431
the SC	18431
OEC cotransplantation group	18440
the DMEM , SC , and OEC groups	18482
3 to 6 weeks	18516
transplantation	18535
Two number signs P < 0.01 vs DMEM group , two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P < 0.01 vs. OEC group Fig. 8 SEP	18552
Two number signs	18552
P	18569
< 0.01 vs DMEM group , two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P < 0.01 vs. OEC group Fig. 8 SEP	18571
< 0.01	18571
<	18571
0.01	18573
DMEM group , two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P < 0.01 vs. OEC group Fig. 8 SEP	18581
DMEM group	18581
two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P < 0.01 vs. OEC group Fig. 8 SEP	18593
two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P < 0.01 vs. OEC group Fig.	18593
two diamonds P < 0.01 vs. SC group , one asterisk P < 0.05 vs. OEC group , two asterisks P	18593
two diamonds	18593
P < 0.01 vs. SC group , one asterisk P	18606
P	18606
0.01	18610
SC group , one asterisk P	18619
SC group	18619
one asterisk P	18629
0.05	18646
OEC group , two asterisks P	18655
OEC group	18655
two asterisks P	18666
two asterisks	18666
P	18680
0.01	18682
OEC group	18691
8 SEP	18707
all experiment groups	18734
the sixth week	18759
transplantation	18780
The amplitude	18797
the latency	18829
the SC + OEC group compared to theDMEM , SC , and OEC groups -LRB- P < 0.05 -RRB- Co-implantation of OECs and SCs Promoted the Migration and Distribution of the Implanted Cells The distribution and migration of transplanted GFP cells in each group were measured at 1 week and 6 weeks post-transplantation	18858
the SC + OEC group compared to theDMEM , SC	18858
the SC + OEC group	18858
theDMEM , SC	18888
OEC groups -LRB- P < 0.05 -RRB- Co-implantation of OECs and SCs Promoted the Migration and Distribution of the Implanted Cells The distribution and migration of transplanted GFP cells in each group were measured at 1 week and 6 weeks post-transplantation	18905
OEC groups	18905
P < 0.05	18917
P	18917
< 0.05	18918
<	18918
0.05	18919
Co-implantation of OECs and SCs	18926
Co-implantation	18926
OECs and SCs	18945
OECs	18945
SCs	18954
the Migration and Distribution of the Implanted Cells The distribution and migration of transplanted GFP cells in each group were measured at 1 week and 6 weeks post-transplantation	18967
the Migration and Distribution	18967
the Implanted Cells The distribution and migration of transplanted GFP cells in each group were measured at 1 week and 6 weeks post-transplantation	19001
the	19001
Cells The distribution and migration of transplanted GFP cells in each group were measured at 1 week and 6 weeks post-transplantation	19015
Cells	19015
The distribution and migration of transplanted GFP cells in each group	19021
The distribution and migration	19021
transplanted GFP cells in each group	19055
transplanted GFP cells	19055
each group	19081
1 week and 6 weeks post-transplantation	19109
1 week	19109
6 weeks post-transplantation	19120
cells	19163
clusters	19190
only very limited cell migration outward	19204
only very limited cell migration	19204
there	19250
no significant differences in the migrated distance and distribution area between each group at 1 week after transplantation	19261
no significant differences	19261
the migrated distance and distribution area between each group at 1 week after transplantation	19291
the	19291
distance and distribution area between each group at 1	19304
distance and distribution area	19304
each group at 1	19343
each group	19343
1	19357
week	19359
transplantation	19370
transplanted cell migration toward adjacent tissues with band-shaped distribution	19396
transplanted cell migration	19396
adjacent tissues with band-shaped distribution	19431
adjacent tissues	19431
band-shaped distribution	19453
6 weeks	19494
addition	19527
co-transplantation of OECs and SCs	19547
co-transplantation	19547
OECs and SCs	19569
green fluorescent cells	19583
the injured area -LRB- Fig. 1 -RRB-	19621
the injured area	19621
Fig. 1	19639
the distribution area of 0.396 ± 0.051 mm2 and migration distance of 2.845 ± 0.448 mm , which were significantly larger and longer than that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19653
the distribution area	19653
0.396 ± 0.051 mm2 and migration distance of 2.845 ± 0.448 mm , which were significantly larger and longer than that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19678
0.396 ± 0.051 mm2	19678
0.396 ±	19678
0.051 mm2	19686
migration distance of 2.845 ± 0.448 mm , which were significantly larger and longer than that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19700
migration distance	19700
2.845 ± 0.448 mm , which were significantly larger and longer than that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19722
2.845 ±	19722
0.448 mm , which were significantly larger and longer than that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19730
0.448 mm	19730
that in the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19788
that	19788
the SC or OEC group -LRB- P < 0.05 , Table 1 -RRB-	19796
the SC or OEC group	19796
P	19817
< 0.05 , Table 1	19818
<	19818
0.05	19819
Table 1	19825
These findings	19835
the grafted cells	19862
6 weeks	19895
co-transplantation	19908
the migration and distribution of the implanted cells in the injured spinal cord	19936
the migration and distribution	19936
the implanted cells in the injured spinal cord	19970
the implanted cells	19970
the injured spinal cord	19993
Co-implantation of OECs and SCs	20018
Co-implantation	20018
OECs and SCs	20037
the Infiltration of Astrocytes and Microglias/Macrophages	20058
the Infiltration	20058
Astrocytes and Microglias/Macrophages	20078
Astrocytes	20078
Microglias/Macrophages	20093
the effects of co-implantation of OECs and SCs	20128
the effects	20128
co-implantation of OECs and SCs	20143
co-implantation	20143
OECs and SCs	20162
astrocyte and microglia/macrophage infiltration	20178
SCI rats	20229
immunohistochemical staining andWestern blotting	20239
1 week post-transplantation	20306
the expression of GFAP -LRB- astrocyte marker -RRB- and Iba1 -LRB- microglia / macrophage marker -RRB- proteins in the injured spinal cord	20349
the expression of GFAP -LRB- astrocyte marker -RRB-	20349
the expression	20349
GFAP	20367
astrocyte marker	20373
Iba1 -LRB- microglia / macrophage marker -RRB-	20395
Iba1	20395
microglia	20401
macrophage marker	20412
macrophage	20412
marker	20423
proteins in the injured spinal cord	20431
proteins	20431
the injured spinal cord	20443
immunohistochemical staining results	20480
the DMEM control group	20532
the expressions of GFAP and Iba1	20556
the expressions	20556
GFAP and Iba1	20575
28.2 ± 8.3 and 51.5 ± 7.7 % in the SC+OEC group , 60.0 ± 11.1 and 75.5 ± 12.6 %	20594
28.2 ± 8.3 and 51.5	20594
7.7 % in the SC+OEC group , 60.0 ± 11.1 and 75.5 ± 12.6 %	20614
7.7 %	20614
the SC+OEC group , 60.0 ± 11.1 and 75.5 ± 12.6 %	20623
the SC+OEC group	20623
60.0 ± 11.1	20641
60.0	20641
11.1	20647
75.5 ± 12.6 %	20656
75.5	20656
12.6 %	20662
the OEC group , and 133.8 ± 19.5 and 98.2 ± 17.9 % in the SC group , respectively -LRB- Fig. 2a , c -RRB-	20672
the OEC group , and 133.8 ± 19.5 and 98.2 ± 17.9 % in the SC group , respectively	20672
the OEC group	20672
133.8	20691
19.5 and 98.2 ± 17.9 % in the SC group , respectively	20699
19.5 and 98.2 ± 17.9 %	20699
19.5 and 98.2	20699
17.9 %	20714
the SC group , respectively	20724
the SC group	20724
Fig. 2a , c	20752
Fig. 2a	20752
c	20761
Western blotting analysis	20768
the densities of GFAP and Iba1 bands	20795
the densities	20795
GFAP and Iba1 bands	20812
the SC+OEC group compared with those in the DMEM , SC , and OEC groups -LRB- P < 0.05 , Fig. 2b , d -RRB-	20860
the SC+OEC group	20860
those in the DMEM , SC , and OEC groups	20891
those	20891
the DMEM , SC , and OEC groups	20900
P < 0.05	20930
P	20930
< 0.05	20931
<	20931
0.05	20932
Fig. 2b , d	20938
Fig. 2b	20938
d	20947
Co-implantation of OECs and SCs	20951
Co-implantation	20951
OECs and SCs	20970
the Expression Levels of Chemokines	20991
the Expression Levels	20991
Chemokines	21016
Factor of Macrophages The expression of chemokines	21040
Factor	21040
Macrophages The expression of chemokines	21050
Macrophages	21050
The expression of chemokines	21062
The expression	21062
chemokines	21080
factor of macrophages at 1	21104
factor	21104
macrophages at 1	21114
macrophages	21114
1	21129
week	21131
transplantation	21142
the infiltration of inflammatory cells and the polarization of macrophages	21190
the infiltration of inflammatory cells	21190
the infiltration	21190
inflammatory cells	21210
the polarization of macrophages	21233
the polarization	21233
macrophages	21253
The expression levels of CCL2 , CCL3 , IL-4 , and IFN-γ in the injured area	21266
The expression levels	21266
CCL2 , CCL3 , IL-4 , and IFN-γ in the injured area	21291
CCL2 , CCL3 , IL-4 , and IFN-γ	21291
the injured area	21322
Western blotting and ELISA	21356
The Western blotting	21384
co-transplantation of OECs and SCs	21425
co-transplantation	21425
OECs and SCs	21447
the levels of IFN-γ , CCL2 , and CCL3	21484
the levels	21484
IFN-γ , CCL2 , and CCL3	21498
IFN-γ	21498
CCL2	21505
CCL3	21515
the levels of IL-4 -LRB- P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 3a , b -RRB-	21534
the levels	21534
IL-4 -LRB- P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 3a , b -RRB-	21548
IL-4	21548
P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 3a , b	21554
P	21554
< 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 3a , b	21555
< 0.05	21555
<	21555
0.05	21557
DMEM , SC , and OEC groups ; Fig. 3a , b	21567
DMEM , SC , and OEC groups	21567
DMEM	21567
SC	21573
OEC groups	21581
Fig. 3a , b	21593
Fig. 3a	21593
b	21602
Similar changes of the chemokines and inducing factor of macrophages	21606
Similar changes	21606
the chemokines and inducing factor of macrophages	21625
the chemokines and inducing factor	21625
macrophages	21663
ELISA -LRB- P < 0.05 , Fig. 3c -RRB-	21694
ELISA	21694
P	21701
< 0.05 , Fig. 3c	21702
<	21702
0.05	21703
Fig. 3c	21709
Co-implantation of OECs and SCs Altered the Activation of Macrophages Immunofluorescent staining of the tissues	21719
Co-implantation	21719
OECs and SCs Altered the Activation of Macrophages Immunofluorescent staining of the tissues	21738
OECs and SCs	21738
the Activation of Macrophages Immunofluorescent staining of the tissues	21759
the Activation	21759
Macrophages Immunofluorescent staining of the tissues	21777
Macrophages	21777
the tissues	21819
1 week post-transplantation	21848
the effects of co-transplantation of OECs and SCs	21888
the effects	21888
co-transplantation of OECs and SCs	21903
co-transplantation	21903
OECs and SCs	21925
macrophage activation	21941
iNOS and CD16/32	21964
the markers of M -LRB- IFN-γ -RRB-	21985
the markers	21985
M -LRB- IFN-γ -RRB-	22000
M	22000
IFN-γ	22002
arginase-1 and CD206	22016
the markers of M -LRB- IL-4 -RRB-	22041
the markers	22041
M -LRB- IL-4 -RRB-	22056
M	22056
IL-4	22058
The results	22065
a lower proportion of iNOS	22089
a lower proportion	22089
iNOS	22111
CD16/32 + cells	22117
CD16/32	22117
cells	22126
the SC + OEC group -LRB- 9.28 ± 1.02 ‰ , P < 0.05 ; Fig. 4a -RRB- when compared to the DMEM -LRB- 34.00 ± 4.96 ‰ -RRB- , SC -LRB- 25.53 ± 2.38 ‰ -RRB- , and OEC -LRB- 16.87 ± 1.26 ‰ -RRB- groups	22145
the SC + OEC group -LRB- 9.28 ± 1.02 ‰	22145
the SC + OEC group	22145
9.28 ± 1.02 ‰	22164
9.28 ±	22164
1.02 ‰	22171
P < 0.05 ; Fig. 4a -RRB- when compared to the DMEM -LRB- 34.00 ± 4.96 ‰ -RRB- , SC -LRB- 25.53 ± 2.38 ‰ -RRB- , and OEC -LRB- 16.87 ± 1.26 ‰ -RRB- groups	22178
P	22178
0.05 ; Fig. 4a	22182
0.05	22182
Fig. 4a	22188
the DMEM -LRB- 34.00 ± 4.96 ‰ -RRB- , SC -LRB- 25.53 ± 2.38 ‰ -RRB- , and OEC -LRB- 16.87 ± 1.26 ‰ -RRB-	22214
the DMEM -LRB- 34.00 ± 4.96 ‰ -RRB-	22214
the DMEM	22214
34.00 ± 4.96 ‰	22224
34.00	22224
4.96 ‰	22231
SC -LRB- 25.53 ± 2.38 ‰ -RRB-	22239
SC	22239
25.53 ± 2.38 ‰	22243
25.53	22243
2.38 ‰	22251
OEC -LRB- 16.87 ± 1.26 ‰ -RRB-	22263
OEC	22263
16.87 ± 1.26 ‰	22268
16.87 ±	22268
1.26 ‰	22276
the numbers of arginase-1 + / CD206 + cells	22303
the numbers	22303
arginase-1 + / CD206 + cells	22318
arginase-1 +	22318
arginase-1	22318
+	22328
CD206 + cells	22330
CD206	22330
cells	22337
higher in the SC+OEC group -LRB- 16.04 ± 3.33 ‰ , P < 0.05 ; Fig. 4b -RRB- than those of the DMEM -LRB- 4.24 ± 0.06 ‰ -RRB- , SC -LRB- 6.91 ± 0.34 ‰ -RRB- , and OEC -LRB- 9.67 ± 2.10 ‰ -RRB- groups	22348
the SC+OEC group	22358
16.04 ± 3.33 ‰ , P < 0.05 ; Fig. 4b -RRB- than those of the DMEM -LRB- 4.24 ± 0.06 ‰ -RRB- , SC -LRB- 6.91 ± 0.34 ‰ -RRB- , and OEC -LRB- 9.67 ± 2.10 ‰	22376
16.04 ± 3.33 ‰	22376
16.04	22376
3.33 ‰	22384
P < 0.05 ; Fig. 4b -RRB- than those of the DMEM -LRB- 4.24 ± 0.06 ‰ -RRB- , SC -LRB- 6.91 ± 0.34 ‰ -RRB- ,	22391
P < 0.05 ; Fig. 4b -RRB-	22391
P	22391
0.05 ; Fig. 4b	22393
0.05	22393
Fig. 4b	22399
those of the DMEM -LRB- 4.24 ± 0.06 ‰ -RRB- , SC -LRB- 6.91 ± 0.34 ‰ -RRB- ,	22413
those of the DMEM	22413
those	22413
the DMEM	22422
4.24 ± 0.06 ‰	22432
4.24 ± 0.06	22432
4.24	22432
0.06	22439
‰	22443
SC -LRB- 6.91 ± 0.34 ‰ -RRB-	22447
SC	22447
6.91 ± 0.34 ‰	22451
6.91	22451
0.34 ‰	22457
OEC -LRB- 9.67 ± 2.10 ‰	22469
OEC	22469
9.67 ± 2.10 ‰	22474
9.67	22474
2.10 ‰	22481
Co-implantation of OECs and SCs	22496
Co-implantation	22496
OECs and SCs	22515
the Expression Levels of Pro- and Anti-inflammatory Factors	22536
the Expression Levels	22536
Pro- and Anti-inflammatory Factors	22561
addition	22599
evaluation of the inflammation environment	22611
evaluation	22611
the inflammation environment	22625
the expression of pro- and anti-inflammatory factors	22655
the expression	22655
pro- and anti-inflammatory factors	22673
the functions and mechanisms of inflammatory cells	22741
the functions and mechanisms	22741
inflammatory cells	22773
The expression levels of TNF-α , IL-6 , IL-10 , and IL-13 in the injured spinal cord	22793
The expression levels	22793
TNF-α , IL-6 , IL-10 , and IL-13 in the injured spinal cord	22818
TNF-α , IL-6 , IL-10 , and IL-13	22818
the injured spinal cord	22851
Western blotting	22894
The results	22912
co-transplantation of OECs and SCs	22936
co-transplantation	22936
OECs and SCs	22958
the levels of IL-6 and TNF-α	22995
the levels	22995
IL-6 and TNF-α	23009
the levels of IL-10 and IL-13 -LRB- P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 5 -RRB-	23039
the levels	23039
IL-10 and IL-13 -LRB- P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 5 -RRB-	23053
IL-10 and IL-13	23053
P < 0.05 , vs. DMEM , SC , and OEC groups ; Fig. 5	23070
P < 0.05 , vs. DMEM , SC ,	23070
P	23070
< 0.05 , vs. DMEM , SC ,	23071
< 0.05	23071
<	23071
0.05	23073
DMEM , SC	23083
OEC groups ; Fig. 5	23097
OEC groups	23097
Fig. 5	23109
These results	23118
co-transplantation	23147
expression of pro-inflammatory factors -LRB- TNF-α and IL-6 -RRB-	23177
expression	23177
pro-inflammatory factors -LRB- TNF-α and IL-6 -RRB-	23191
pro-inflammatory factors	23191
TNF-α and IL-6	23217
TNF-α	23217
IL-6	23227
the expression of anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	23247
the expression	23247
anti-inflammatory factors	23265
IL-10 and IL-13	23292
IL-10	23292
IL-13	23302
the CNS after SCI	23312
the CNS	23312
SCI	23326
Co-implantation of OECs and SCs	23331
Co-implantation	23331
OECs and SCs	23350
the Area of Cystic Cavities At 6 weeks post-transplantation , the injured part of the spinal cord in the DMEM group was more transparent and thinner than that of the SC , OEC , and SC+OEC groups in gross morphology	23371
the Area	23371
Cystic Cavities	23383
6 weeks	23402
the injured part of the spinal cord in the DMEM group	23432
the injured part	23432
the spinal cord in the DMEM group	23452
the spinal cord	23452
the DMEM group	23471
that of the SC , OEC , and SC+OEC groups in gross morphology	23524
that	23524
the SC , OEC , and SC+OEC groups in gross morphology	23532
the SC	23532
OEC	23540
SC+OEC groups in gross morphology	23549
SC+OEC groups	23549
gross morphology	23566
a light microscope	23590
larger cystic cavities	23610
6.083 ± 0.566 mm2	23645
6.083 ± 0.566	23645
6.083	23645
0.566	23651
mm2	23657
the DMEM group	23665
The cystic cavities in the SC+OEC group -LRB- 1.183 ± 0.189 mm2 -RRB-	23681
The cystic cavities in the SC+OEC group	23681
The cystic cavities	23681
the SC+OEC group	23704
1.183 ± 0.189 mm2	23722
1.183 ± 0.189	23722
1.183	23722
0.189	23728
mm2	23734
P < 0.05	23759
P	23759
< 0.05	23761
<	23761
0.05	23763
those of the DMEM , SC -LRB- 3.050 ± 0.760 mm2 -RRB- , and OEC -LRB- 2.327 ± 0.581 mm2 , Fig. 6 -RRB- groups	23782
those of the DMEM	23782
those	23782
the DMEM	23791
SC -LRB- 3.050 ± 0.760 mm2 -RRB-	23801
SC	23801
3.050 ± 0.760 mm2	23805
3.050	23805
0.760 mm2	23812
OEC -LRB- 2.327 ± 0.581 mm2 , Fig. 6 -RRB- groups	23828
OEC -LRB- 2.327 ± 0.581 mm2 , Fig. 6 -RRB-	23828
OEC	23828
2.327 ± 0.581 mm2 , Fig. 6	23833
2.327 ± 0.581 mm2	23833
2.327	23833
0.581 mm2	23839
Fig. 6	23850
groups	23858
Co-implantation of OECs and SCs	23866
Co-implantation	23866
OECs and SCs	23885
the Recovery of Motor Function	23907
the Recovery	23907
Motor Function	23923
the Contused Rats The motor function was assessed using the BBB score -LRB- n = 6 / group -RRB-	23941
the Contused Rats	23941
The motor function	23959
the BBB score -LRB- n = 6 / group -RRB-	23997
the BBB score	23997
n = 6 / group	24012
n	24012
= 6 / group	24013
= 6	24013
group	24017
One day	24025
SCI	24039
all injured rats	24044
no observable hind limb movement -LRB- BBB = 0 -RRB-	24082
no observable hind limb movement	24082
BBB	24116
0	24121
the DMEM group	24128
significant motor disturbance	24144
the hind limbs of the rats at 1	24187
the hind limbs	24187
the rats at 1	24205
the rats	24205
1	24217
week	24219
some degree of recovery	24229
some degree	24229
recovery	24244
a functional plateau -LRB- BBB = 7.00 ± 1.25 -RRB-	24288
a functional plateau	24288
BBB = 7.00 ± 1.25	24310
BBB	24310
= 7.00 ± 1.25	24313
= 7.00	24313
1.25	24321
6 weeks	24330
an improved motor function	24350
the SC or OEC group	24395
BBB scores of 9.50 ± 0.701 -LRB- SC group -RRB- and 10.20 ± 1.69 -LRB- OEC group -RRB-	24421
BBB scores	24421
9.50 ± 0.701 -LRB- SC group -RRB- and 10.20 ± 1.69 -LRB- OEC group -RRB-	24435
9.50 ± 0.701 -LRB- SC group -RRB- and 10.20 ± 1.69	24435
9.50 ± 0.701 -LRB- SC group -RRB-	24435
9.50	24435
± 0.701 -LRB- SC group -RRB-	24440
± 0.701	24440
SC group	24449
10.20 ± 1.69	24463
10.20	24463
1.69	24471
OEC group	24477
the co-transplanted group showed markedly better functional recovery , with a significantly increased BBB	24507
the co-transplanted group	24507
markedly better functional recovery	24540
a significantly increased BBB	24582
locomotor score -LRB- BBB = 13.70 ± 1.25 -RRB- compared to that of the DMEM , SC , and OEC groups at 6 weeks	24612
locomotor score -LRB- BBB = 13.70 ± 1.25 -RRB-	24612
locomotor score	24612
BBB = 13.70 ± 1.25	24629
BBB	24629
= 13.70 ± 1.25	24632
= 13.70	24632
1.25	24641
that of the DMEM , SC , and OEC groups at 6 weeks	24659
that	24659
the DMEM , SC , and OEC groups	24667
6 weeks	24699
Fig. 7	24708
SEP	24717
the end of the sixth week	24739
the end	24739
the sixth week	24750
transplantation , which could be recorded in all the experimental groups -LRB- Fig. 8 -RRB-	24771
transplantation	24771
all the experimental groups -LRB- Fig. 8 -RRB-	24815
all the experimental groups	24815
Fig. 8	24844
The amplitude	24853
the latency	24885
the SC+OEC group	24914
the amplitude of 30.19 ± 3.76 mV and the latency of 18.8 ± 1.31 ms compared to 5.12 ± 0.82 mV and 43.6 ± 5.57 ms	24936
the amplitude	24936
30.19 ± 3.76 mV and the latency of 18.8 ± 1.31 ms compared to 5.12 ± 0.82 mV and 43.6 ± 5.57 ms	24953
30.19 ± 3.76 mV	24953
30.19 ±	24953
3.76 mV	24961
the latency of 18.8 ± 1.31 ms compared to 5.12 ± 0.82 mV and 43.6 ± 5.57 ms	24973
the latency	24973
18.8 ± 1.31 ms compared to 5.12 ± 0.82 mV and 43.6 ± 5.57 ms	24988
18.8 ± 1.31 ms	24988
5.12 ± 0.82 mV and 43.6 ± 5.57 ms	25015
5.12 ± 0.82 mV	25015
5.12 ±	25015
0.82 mV	25022
43.6 ± 5.57 ms	25034
43.6	25034
5.57 ms	25041
the DMEM group	25052
15.27 ±	25068
1.15 mV and 36.4	25076
1.15 mV	25076
36.4	25088
3.12 ms in the SC group , and 18.87	25095
3.12 ms	25095
the SC group	25106
18.87	25124
2.11 mV	25132
32.2 ±	25144
2.19 ms in the OEC group -LRB- P < 0.05 , Fig. 8 -RRB-	25151
2.19 ms	25151
the OEC group -LRB- P < 0.05 , Fig. 8 -RRB-	25162
the OEC group	25162
P	25177
< 0.05 , Fig. 8	25178
<	25178
0.05	25179
Fig. 8	25185
Discussion	25195
the present study	25209
a rat contused model of SCI	25228
a rat	25228
model of SCI	25243
model	25243
SCI	25252
the effects of co-transplantation of OECs and SCs	25280
the effects	25280
co-transplantation of OECs and SCs	25295
co-transplantation	25295
OECs and SCs	25317
infiltration and activation of inflammatory cells , improvements in the sub-acute immune microenvironment , and the subsequent reconstruction of spinal cord structures and recovery of motor function	25333
infiltration and activation of inflammatory cells	25333
infiltration and activation	25333
inflammatory cells	25364
improvements in the sub-acute immune microenvironment	25384
improvements	25384
the sub-acute immune microenvironment	25400
the subsequent reconstruction of spinal cord structures and recovery of motor function	25443
the subsequent reconstruction of spinal cord structures	25443
the subsequent reconstruction	25443
spinal cord structures	25476
recovery of motor function	25503
recovery	25503
motor function	25515
The results	25531
survival and more extensive migration of sub-acute co-transplanted OECs and SCs in the damaged tissues	25550
survival	25550
more extensive migration of sub-acute co-transplanted OECs and SCs in the damaged tissues	25563
more extensive migration	25563
sub-acute co-transplanted OECs and SCs in the damaged tissues	25591
sub-acute co-transplanted OECs and SCs	25591
the damaged tissues	25633
co-transplantation of both cells	25667
co-transplantation	25667
both cells	25689
the activation of astrocytes and infiltration of microglias/macrophages	25713
the activation	25713
astrocytes and infiltration	25731
microglias/macrophages	25762
The expressions of CCL2 and CCL3 , important chemokines for recruitment of immune cells ,	25786
The expressions of CCL2 and CCL3	25786
The expressions	25786
CCL2 and CCL3	25805
important chemokines for recruitment of immune cells	25820
important chemokines	25820
recruitment of immune cells	25845
recruitment	25845
immune cells	25860
Subtype analysis of macrophages	25895
Subtype analysis	25895
macrophages	25915
SC+OEC co-transplantation	25939
the amount of M -LRB- IL-4 -RRB- macrophages	25980
the amount	25980
M -LRB- IL-4 -RRB- macrophages	25994
IL-4	25996
the amount of M -LRB- IFN-γ -RRB- macrophages , accompanied with increased expression of IL-4	26025
the amount	26025
M	26039
IFN-γ	26041
macrophages , accompanied with increased expression of IL-4	26048
macrophages	26048
increased expression of IL-4	26078
increased expression	26078
IL-4	26102
expression of IFN-γ	26121
expression	26121
IFN-γ	26135
the immunity microenvironment of the injured cord	26148
the immunity microenvironment	26148
the injured cord	26181
co-transplantation , indicated by the decreased pro-inflammatory factor -LRB- TNF-α and IL-6 -RRB- expression and the increased anti-inflammatory factor -LRB- IL-10 and IL-13 -RRB- expression	26218
co-transplantation	26218
the decreased pro-inflammatory factor -LRB- TNF-α and IL-6 -RRB- expression and the increased anti-inflammatory factor -LRB- IL-10 and IL-13 -RRB- expression	26251
the decreased pro-inflammatory factor -LRB- TNF-α and IL-6 -RRB- expression	26251
the decreased pro-inflammatory factor -LRB- TNF-α and IL-6 -RRB-	26251
the decreased pro-inflammatory factor	26251
TNF-α and IL-6	26290
TNF-α	26290
IL-6	26300
expression	26306
the increased anti-inflammatory factor -LRB- IL-10 and IL-13 -RRB- expression	26321
the increased anti-inflammatory factor -LRB- IL-10 and IL-13 -RRB-	26321
the increased anti-inflammatory factor	26321
IL-10 and IL-13	26361
IL-10	26361
IL-13	26371
expression	26378
These changes that occurred after co-transplantation might be associated with the reconstruction of tissue structures and the recovery of hind limb movement	26390
These changes	26390
co-transplantation	26424
the reconstruction of tissue structures and the recovery of hind limb movement	26468
the reconstruction of tissue structures	26468
the reconstruction	26468
tissue structures	26490
the recovery of hind limb movement	26512
the recovery	26512
hind limb movement	26528
the contused rats	26559
Previous studies	26578
OECs and SCs	26611
several common features	26630
-LSB- 20	26654
22 -RSB-	26658
instance	26667
both cell types	26677
multiple cytokines including nerve growth factor , brain-derived neurotrophic factor , neurotrophin-3 , and fibroblast growth factor	26713
multiple cytokines	26713
nerve growth factor , brain-derived neurotrophic factor , neurotrophin-3 , and fibroblast growth factor	26742
nerve growth factor	26742
brain-derived neurotrophic factor	26763
neurotrophin-3	26798
fibroblast growth factor	26818
addition	26847
OECs and SCs	26857
antigenic and morphological features and transcriptional regulation mechanisms	26876
antigenic and morphological features	26876
transcriptional regulation mechanisms	26917
a cellular microenvironment that favors the repair of damage	26967
a cellular microenvironment	26967
the repair of damage	27007
the repair	27007
damage	27021
the CNS	27031
-LSB- 22 , 23 -RSB-	27039
OECs	27049
higher migration ability allowing extensive distribution and promoting better regeneration of spinal nerve fibers than SCs , which have lesser capacity for migration but have greater remyelination ability -LSB- 17 , 24 -RSB-	27059
higher migration ability	27059
extensive distribution	27093
better regeneration of spinal nerve fibers	27130
better regeneration	27130
spinal nerve fibers	27153
SCs , which have lesser capacity for migration but have greater remyelination ability -LSB- 17 , 24 -RSB-	27178
SCs	27178
lesser capacity for migration	27194
lesser capacity	27194
migration	27214
greater remyelination ability -LSB- 17 , 24 -RSB-	27233
greater remyelination ability	27233
17	27264
It	27273
co-transplantation of OECs and SCs	27314
co-transplantation	27314
OECs and SCs	27336
spinal contusions in rats	27370
spinal contusions	27370
rats	27391
the regeneration of myelinated axons and the growth of 5-hydroxytryptamine fibers	27409
the regeneration of myelinated axons	27409
the regeneration	27409
myelinated axons	27429
the growth of 5-hydroxytryptamine fibers	27450
the growth	27450
5-hydroxytryptamine fibers	27464
hind limb motor function in injured rats	27520
hind limb motor function	27520
injured rats	27548
-LSB- 11 , 12 -RSB-	27561
the present study	27574
we	27593
co-transplantation of both cells	27622
co-transplantation	27622
both cells	27644
the migration of grafted cells in the recipient tissues	27680
the migration	27680
grafted cells in the recipient tissues	27697
grafted cells	27697
the recipient tissues	27714
more extensive distribution	27748
the damaged areas	27779
addition	27801
the present results	27811
co-transplantation	27848
substantial improvement in tissue structure	27879
substantial improvement	27879
tissue structure	27906
lower cavity area and motor function	27926
lower cavity area	27926
motor function	27948
higher open-field BBB score and superior SEP.	27966
higher open-field BBB score	27966
superior SEP.	27998
Inflammation	28012
a part of the initial response to the injury of CNS	28028
a part	28028
the initial response to the injury of CNS	28038
the initial response	28038
the injury of CNS	28062
the injury	28062
CNS	28076
the acute phase	28104
disruption of the blood brain/spinal barrier	28123
disruption	28123
the blood brain/spinal barrier	28137
accumulation of immune cells and proteins	28174
accumulation	28174
immune cells and proteins	28190
the acute phase , which typically lasts for a few hours	28224
the acute phase	28224
a few hours	28267
pro-inflammatory cytokines	28280
-LSB- 25 , 26 -RSB-	28323
This phase	28333
an augmentation in damage	28364
an augmentation	28364
damage	28383
-LSB- 25 , 27 -RSB-	28390
the sub-acute phase	28403
between 2 and 7 days after injury	28424
between 2 and 7 days	28424
injury	28451
the levels of some pro-inflammatory cytokines	28459
the levels	28459
some pro-inflammatory cytokines	28473
the number of macrophages and T cells	28535
the number	28535
macrophages and T cells	28549
the levels of anti-inflammatory factors	28590
the levels	28590
anti-inflammatory factors	28604
-LSB- 26 , 28 -RSB-	28641
It	28651
inflammation	28678
regeneration	28703
the later phase	28719
-LSB- 28 , 29 -RSB-	28735
the characteristic of the sub-acute phase	28756
the characteristic	28756
the sub-acute phase	28778
a transformation from aggravation to repair of SCI -LSB- 30 , 31 -RSB-	28801
a transformation	28801
aggravation to repair of SCI -LSB- 30 , 31 -RSB-	28823
aggravation	28823
repair of SCI -LSB- 30 , 31 -RSB-	28838
repair	28838
SCI -LSB- 30 , 31 -RSB-	28848
co-transplantation ofOECs and SCs for regulating the inflammation microenvironment	28874
co-transplantation ofOECs and SCs	28874
the inflammation microenvironment	28923
the sub-acute phase	28972
SCI	28998
The chemotactic factor -LRB- CCL2 and CCL3 -RRB-	29003
The chemotactic factor	29003
CCL2 and CCL3	29027
CCL2	29027
CCL3	29036
astrocytes and microglias	29054
an injured region	29113
Astrocytes and microglias , major immune mediators in the CNS , release amounts of inflammatory factors in an inflammatory cascade , and exacerbate secondary pathological damage .	29132
Astrocytes and microglias	29132
major immune mediators in the CNS , release amounts of inflammatory factors in an inflammatory cascade , and exacerbate secondary pathological damage	29159
major immune mediators	29159
the CNS , release amounts of inflammatory factors in an inflammatory cascade , and exacerbate secondary pathological damage	29185
the CNS	29185
release amounts of inflammatory factors in an inflammatory cascade	29194
release amounts	29194
inflammatory factors in an inflammatory cascade	29213
inflammatory factors	29213
an inflammatory cascade	29237
secondary pathological damage	29277
Activated astrocytes	29308
glial scars , which block axonal regeneration and repair of nerve cells -LSB- 32 , 33 -RSB-	29343
glial scars	29343
axonal regeneration and repair of nerve cells	29368
axonal regeneration and repair	29368
nerve cells	29402
-LSB- 32 , 33	29414
microglias	29434
macrophages , which phagocytize debris and degenerated myelin sheath	29464
macrophages	29464
debris	29495
myelin sheath	29518
The reduced CCL2 and CCL3 expression	29533
the restriction of monocyte/macrophage infiltration	29586
the restriction	29586
monocyte/macrophage infiltration	29605
the CNS -LSB- 34 -RSB-	29643
the CNS	29643
34 -RSB-	29652
It	29657
this study that co-transplantation of OECs and SCs significantly reduced the expression of CCL2 and CCL3 , and thus reduced the activation of astrocytes , as well as the infiltration of macrophages	29676
this study	29676
co-transplantation of OECs and SCs	29692
co-transplantation	29692
OECs and SCs	29714
the expression of CCL2 and CCL3	29749
the expression	29749
CCL2 and CCL3	29767
the activation of astrocytes , as well as the infiltration of macrophages	29799
the activation of astrocytes	29799
the activation	29799
astrocytes	29817
the infiltration of macrophages	29840
the infiltration	29840
macrophages	29860
Astrocytes	29873
a major type of gliocyte	29888
a major type	29888
gliocyte	29904
a key role	29922
nerve regeneration in the CNS	29936
nerve regeneration	29936
the CNS	29958
it	29979
astrocytes	30005
hypertrophy	30024
contact with SCs	30044
contact	30044
SCs	30057
OECs	30074
35 -RSB-	30089
our previous study in vivo	30104
our previous study	30104
vivo	30126
SCs	30146
more GFAP expression	30157
OECs	30183
SCs	30193
OECs on the reaction of astrocytes -LSB- 17 -RSB-	30209
OECs	30209
the reaction of astrocytes -LSB- 17 -RSB-	30217
the reaction	30217
astrocytes -LSB- 17 -RSB-	30233
astrocytes	30233
17 -RSB-	30245
the present study	30253
the expression of GFAP in the co-transplantation group	30272
the expression	30272
GFAP in the co-transplantation group	30290
GFAP	30290
the co-transplantation group	30298
that of other groups	30356
that	30356
other groups	30364
the co-transplantation of SCs and OECs	30386
the co-transplantation	30386
SCs and OECs	30412
a synergistic effect rather than a superposition effect	30432
a synergistic effect	30432
a superposition effect	30465
the astrocytes	30491
the mechanisms for this synergistic effect	30511
the mechanisms	30511
this synergistic effect	30530
further studied	30564
further	30564
Macrophages , which are a type of highly differentiated , mature mononuclear phagocytic cell ,	30581
Macrophages	30581
a type of highly differentiated	30604
a type	30604
mature mononuclear phagocytic cell	30637
monocytes that migrate from blood to the tissues and microglias that reside in the CNS	30697
monocytes	30697
blood	30725
the tissues and microglias that reside in the CNS	30734
the tissues and microglias	30734
the CNS	30776
Macrophages	30785
a heterogeneous cell population that exert different functions depending on the microenvironment -LSB- 13 , 36 -RSB-	30801
a heterogeneous cell population	30801
different functions	30844
the microenvironment	30877
-LSB- 13 , 36 -RSB-	30898
The activation of macrophages	30908
The activation	30908
macrophages	30926
the expression of receptors , cytokines , and chemokines , as well as differences in effector functions	30954
the expression of receptors , cytokines , and chemokines	30954
the expression	30954
receptors , cytokines , and chemokines	30972
differences in effector functions	31021
differences	31021
effector functions	31036
IFN-γ-induced macrophages	31056
oxidative metabolism	31090
the expression of pro-inflammatory factors	31126
the expression	31126
pro-inflammatory factors	31144
anti-infective effects	31184
positive immune responses	31215
the concomitant release of oxidative metabolites and proteolytic enzymes	31251
the concomitant release	31251
oxidative metabolites and proteolytic enzymes	31278
oxidative metabolites	31278
proteolytic enzymes	31304
neurons and glial cells	31337
neurons	31337
glial cells	31349
toxic effects	31371
neurons	31388
IL-4-induced macrophages	31397
immune responses , improve angiogenesis , inhibit pro-inflammatory responses , mediate the immune escape of pathogens , and promote the regeneration and growth of mature sensory axons -LSB- 37 , 38 -RSB-	31435
immune responses	31435
angiogenesis	31461
pro-inflammatory responses	31483
the immune escape of pathogens	31519
the immune escape	31519
pathogens	31540
the regeneration and growth of mature sensory axons -LSB- 37	31563
the regeneration and growth	31563
mature sensory axons -LSB- 37	31594
mature sensory axons	31594
37	31616
The r	31625
s u	31633
s	31633
u	31635
l	31637
t s of the present s tudy	31639
t s	31639
the present s tudy	31646
co-transplantation of OECs and SCs	31677
co-transplantation	31677
OECs and SCs	31699
the M -LRB- IL-4 -RRB- increase	31726
IL-4	31733
the M -LRB- IFN-γ -RRB-	31758
the M	31758
IFN-γ	31764
numbers	31771
IL-6 and TNF-α , major pro-inflammatory factors ,	31780
IL-6 and TNF-α	31780
major pro-inflammatory factors	31796
immune functions and inflammatory responses	31849
immune functions	31849
inflammatory responses	31870
These factors	31894
a network to influence the formation of immune molecules including antibodies and complement , and to induce extensive inflammatory responses through the chemotactic effects and degranulation of neutrophils and monocytes/macrophages -LSB- 29 -RSB-	31920
the formation of immune molecules including antibodies and complement	31943
the formation	31943
immune molecules including antibodies and complement	31960
immune molecules	31960
antibodies and complement	31987
antibodies	31987
complement	32002
extensive inflammatory responses	32028
the chemotactic effects and degranulation of neutrophils and monocytes/macrophages	32069
the chemotactic effects	32069
degranulation of neutrophils and monocytes/macrophages	32097
degranulation	32097
neutrophils and monocytes/macrophages	32114
29 -RSB-	32153
the CNS	32161
synthesis or secretion of these pro-inflammatory factors	32170
synthesis or secretion	32170
these pro-inflammatory factors	32196
neuronal degeneration	32235
the progression of repair and regeneration	32274
the progression	32274
repair and regeneration	32293
39 -RSB-	32318
trace levels of these cytokines	32336
trace levels	32336
these cytokines	32352
cascade effects , which not only increase inflammatory responses but also destroy the internal environment of the CNS -LSB- 31 -RSB-	32381
cascade effects	32381
inflammatory responses	32422
the internal environment of the CNS -LSB- 31 -RSB-	32462
the internal environment	32462
the CNS -LSB- 31 -RSB-	32490
the CNS	32490
31 -RSB-	32499
levels of pro-inflammatory factors	32514
levels	32514
pro-inflammatory factors	32524
the damage caused by excessive immune cell activation	32561
the damage	32561
excessive immune cell activation	32582
the subsequent cytotoxic and apoptotic effects	32631
addition	32682
the increased expression and secretion of anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	32692
the increased expression	32692
secretion of anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	32721
secretion	32721
anti-inflammatory factors -LRB- IL-10 and IL-13 -RRB-	32734
anti-inflammatory factors	32734
IL-10 and IL-13	32761
IL-10	32761
IL-13	32771
immune-mediated damage caused by excessive inflammation -LSB- 40 , 41 -RSB-	32798
immune-mediated damage	32798
excessive inflammation	32831
-LSB- 40 , 41 -RSB-	32854
The present results	32864
co-transplantation of OECs and SCs	32896
co-transplantation	32896
OECs and SCs	32918
the immune microenvironment	32945
the injured area	32976
selective anti-inflammatory effects	33000
the damage caused by harmful immune responses	33047
the damage	33047
harmful immune responses	33068
neuro-protective effects	33116
summary	33145
the findings of the present study	33154
the findings	33154
the present study	33170
co-transplantation of OECs and SCs	33198
co-transplantation	33198
OECs and SCs	33220
the activation and infiltration of inflammatory cells	33243
the activation and infiltration	33243
inflammatory cells	33278
macrophage activation	33311
the M -LRB- IL-4 -RRB- phenotype rather than M	33336
the M -LRB- IL-4 -RRB- phenotype	33336
M	33370
IFN-γ	33373
This effect	33381
the changes of anti- and/or pro-inflammatory factor expression , which provide an inflammatory response environment that favors repair of the structure and function of the injured spinal cord	33427
the changes	33427
anti- and/or pro-inflammatory factor expression	33442
anti-	33442
pro-inflammatory factor expression	33455
an inflammatory response environment that favors repair of the structure and function of the injured spinal cord	33505
an inflammatory response environment	33505
repair of the structure and function of the injured spinal cord	33554
repair	33554
the structure and function of the injured spinal cord	33564
the structure and function	33564
the injured spinal cord	33594
